8 Endocrinology Headlines You Missed in April 2026

April was a packed month for endocrinology, with several decisions by the US Food and Drug Administration (FDA) and multiple major trial results reported. Additionally, the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, capped off the month with a series of key clinician insights on everything from GLP-1s in type 1 diabetes (T1D) to the effects of excess iodine on the thyroid.

With all of the news released over the last month, the editorial team at HCPLive have collected 8 of the most impactful headlines below. Catch up on anything you might have missed as we move into May:

FDA News

FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List, With Raechel Sood, NP

On April 30, the FDA announced a proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list. If approved, this decision could outright prevent medical facilities from compounding these medications, thereby cutting down on the risk of exposure to unapproved concentrations or distillations. Rachael Sood, NP, discusses the proposal and its implications for patients living with type 2 diabetes (T2D) or obesity.

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

On April 22, the FDA announced an extension to its prior approval of teplizumab-mzwv, allowing for the treatment of children ≥1 year of age with stage 2 T1D. The decision is a result of positive data from the PETITE-T1D study, which demonstrated that the safety and tolerability of teplizumab in younger children is consistent with that of older populations.

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

On April 1, the FDA announced the groundbreaking approval of orforglipron, the first oral GLP-1 RA that can be taken at any time of day without restrictions on food and water intake. Based on results from the ATTAIN clinical trial program, orforglipron helps patients lose excess body weight and keep the weight off when taken alongside a reduced-calorie diet and increased physical activity.

Trial Updates

Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD

The CAHtalyst Adult study has indicated crinecerfont’s efficacy in reducing glucocorticoid doses among patients with classic congenital adrenal hyperplasia (CAH). These 2-year results from the ongoing trial were presented by Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, at AACE 2026, and highlighted substantial retention during the entire 2-year extension of the trial.

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

A secondary analysis of the GRACE trial has indicated relacorilant’s capacity for reducing cortisol in patients taking GLP-1 RAs for Cushing syndrome. Julie Silverstein, MD, medical director of the pituitary center and of the clinical trials units at WashU Medicine, discusses the difficult pathway between excess cortisol and a series of long-term health detriments, as well as relacorilant’s capacity to offset these connections.

Conference Headlines

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD

Delivered by Shashank Joshi at AACE 2026, this presentation highlights the risk of both too little and too much iodine in the body. Despite the former being well documented over the years, excess iodine can present with many the same symptoms and be just as dangerous. Joshi also covers the narrow window of opportunity between the 2 extremes, emphasizing the importance of managing iodine intake by monitoring the use of nutritional supplements and iodized salt – among other easy ways of overdosing.

Continuous Ketone Monitoring in Diabetes: Clinical Potential and Future Impact, With Rodolfo Galindo, MD

At AACE 2026, Rodolfo Galindo, MD, discussed the promising future of continuous ketone monitoring, which is currently in development in the US. Galindo described the devices as not solely built for measuring ketones, but also for uncovering patterns that point-in-time testing is incapable of capturing. Given that current measurements fail to reflect the body’s constant fluctuations, continuous monitoring can provide a more effective and productive method of predicting diabetic ketoacidosis.

Diabetes Dialogue: Expanding GLP-1 Usage Into Type 1 Diabetes With Viral Shah, MD

In this episode of Diabetes Dialogue, recorded on-site at AACE 2026, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, invite Viral Shah, MD, onto the show to discuss implementing GLP-1 RAs into T1D care. Shah points out the interplay between T1D and obesity, the latter of which is poorly controlled with standard insulin therapy. Given GLP-1 RAs’ efficacy in lowering excess adiposity, Shah posits that they could provide substantial and lasting benefits for patients.